Specialty Hub

In-depth learning materials and relevant resources by areas of interest.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Cardiology

Assorted resources on conditions connected to Cardiology.

Dermatology

Latest information on diseases in Dermatology.

Endocrinology

A detailed look at conditions connected to Endocrinology.

Gastroenterology and Hepatology

In-depth material on Gastroenterology and Hepatology.

Haematology

Assorted resources on conditions connected to Haematology.

Immunology

Immunology, the immune system and immune-mediated diseases.

Infectious Diseases

A detailed look at conditions connected to Infectious Diseases.

Nephrology

Assorted resources on conditions related to Nephrology.

Neurology (CNS) and Pain

Learning materials and guidelines on Neurology (CNS) and Pain.

Oncology

A detailed look at conditions connected to Oncology.

Ophthalmology

Assorted resources on conditions connected to Ophthalmology.

Respiratory

In-depth material on Respiratory conditions.

Rheumatology

Latest information on diseases in Rheumatology.

Urology

Learning materials and guidelines on Urology.

Latest news

Drug news

Phase III DELTA 1 trial of Corectim 0.5% ointment meets primary endpoint in chronic hand eczema

LEO Pharma announced positive results of the DELTA 1 trial

1 mins

Drug news

European Medicines Agency accepts tofersen MAA to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis

Biogen Inc.announced the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for review of tofersen, an investigational drug for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). SOD1-ALS is a progressive and uniformly fatal disease that affects less than 1,000 people in Europe

1 min

Drug news

Data from phase III monarchE trial of adjuvant Verzenio plus ET showing deepening benefit in early breast cancer published in The Lancet Oncology

Eli Lilly announced updated results from the pivotal Phase III monarchE trial of adjuvant Verzenio (abemaciclib) in combination with standard endocrine therapy (ET) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high risk early breast cancer (EBC)

2 min

See all news

You may be interested in...

Learning Zone Homepage

Pompe Disease: Key findings from WMS 2022

Review developments in Pompe disease, expert opinion and discussion, and more in the following pages. Highlights and forthcoming expert content focus on the 2022 World Muscle Society Congress which was held in Halifax, Canada 11–15 October.

Other insights

Innovations in cancer therapy: antibody-drug conjugates

Trastuzumab deruxtecan, a new antibody–drug conjugate, was approved by the US Food and Drug Administration in August 2022 for treatment of metastatic HER2-low breast cancer, a subtype unresponsive to standard anti-HER2 therapy

Other insights

Chronotherapy: introducing the circadian rhythms into treatment landscapes

Discover Chronotherapy: introducing the circadian rhythms into treatment landscapes in this article.